Study In Circulation Questions Cost Effectiveness Of VADs
This article was originally published in The Gray Sheet
A recent analysis of the cost effectiveness of ventricular assist devices used as destination therapy for heart failure suggests room for improvement.
You may also be interested in...
“Looking forward, we anticipate that the DT indication will continue to drive growth across the spectrum of centers, but with an increasingly important contribution from smaller transplant and open heart centers,” CEO Gerhard Burbach said.
CMS opens national coverage analysis on VADs, proposes regulatory reform and announces new ESRD initiative. More reimbursement news.
The pilot trial, cosponsored by NIH, will give ventricular assist devices a chance to prove their worth in heart failure patients not yet in the final stage of their illness.